Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

A bit silly perhaps, but the dance represents a serious step for China’s tech industry. After years of American companies ...

In a survey by PwC early this month, 48% of U.S. executives cited economic policy among the three top factors influencing ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Honor enters the robotics race, backed by a $10B AI strategy, setting humanoid speed records and building smart tech ecosystems.

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

Hearing about artificial intelligence from inside Chinese business paints a very different picture of the tech than popularly ...